Eiropas Savienība - angļu - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

Eiropas Savienība - angļu - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

Eiropas Savienība - angļu - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv)

Eiropas Savienība - angļu - EMA (European Medicines Agency)

astrazeneca ab - palivizumab - respiratory syncytial virus infections - immune sera and immunoglobulins, - synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (rsv) in children at high risk for rsv disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the rsv season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.

Kanāda - angļu - Health Canada

abbvie corporation - palivizumab - powder for solution - 50mg - palivizumab 50mg - monoclonal antibodies

Kanāda - angļu - Health Canada

abbvie corporation - palivizumab - powder for solution - 100mg - palivizumab 100mg - monoclonal antibodies

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

samsung bioepis nz limited - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose dihydrate water for injection - byooviz is indicated for: - the treatment of neovascular (wet) age-related macular degeneration (amd), - the treatment of visual impairment due to diabetic macular oedema (dme), - treatment of proliferative diabetic retinopathy (pdr), - the treatment of visual impairment due to choroidal neovascularisation (cnv), - the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), - the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo).

Kanāda - angļu - Health Canada

astrazeneca canada inc - palivizumab - solution - 100mg - palivizumab 100mg - monoclonal antibodies

Kanāda - angļu - Health Canada

astrazeneca canada inc - palivizumab - solution - 50mg - palivizumab 50mg - monoclonal antibodies

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - ranibizumab, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; histidine - raniviz (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd),,? the treatment of visual impairment due to diabetic macular oedema (dme),,? treatment of proliferative diabetic retinopathy (pdr),,? the treatment of visual impairment due to choroidal neovascularisation,,? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,not recommended for use in preterm infants.